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Introduction
While the incidence of AIDS-defining cancers (ADC) has 
decreased among persons living with HIV/AIDS (PLWHA) in the 
antiretroviral therapy era, the number of non-AIDS-defining cancer 
(NADC) diagnoses is increasing, mainly due to the growth and aging of 
the PLWHA population [1]. Furthermore, NADC risk among PLWHA 
compared to uninfected persons is elevated [2-4]. Given the growing 
interest in the cancer burden in PLWHA, we sought to examine how 
different sources of cancer diagnosis data influence epidemiologic 
analyses.
Studies of cancer incidence among PLWHA have used International 
Classification of Diseases, Ninth Revision (ICD-9) codes[5]in claims 
databases to identify cancer diagnoses [6-8]. Claims data are primarily 
used for administrative purposes, such that their accuracy for 
epidemiologic investigations is variable. Investigators have assessed the 
validity of various algorithms usingICD-9 diagnosis and/or procedure 
codes for ascertaining incident cancer cases, and have observed varying 
Abstract
Background: Given the growing interest in the cancer burden in persons living with HIV/AIDS, we examined the 
validity of data sources for cancer diagnoses (cancer registry versus International Classification of Diseases, Ninth 
Revision [ICD-9 codes]) and compared the association between HIV status and cancer risk using each data source in the 
Veterans Aging Cohort Study (VACS), a prospective cohort of HIV-infected and uninfected veterans from 1996 to 2008.
Methods: We reviewed charts to confirm potential incident cancers at four VACS sites. In the entire cohort, we 
calculated cancer-type-specific age-, sex-, race/ethnicity-, and calendar-period-standardized incidence rates and 
incidence rate ratios (IRR) (HIV-infected versus uninfected). We calculated standardized incidence ratios (SIR) to 
compare VACS and Surveillance, Epidemiology, and End Results rates. 
Results: Compared to chart review, both Veterans Affairs Central Cancer Registry (VACCR) and ICD-9 diagnoses 
had approximately 90% sensitivity; however, VACCR had higher positive predictive value (96% versus 63%). There 
were 6,010 VACCR and 13,386 ICD-9 incident cancers among 116,072 veterans. Although ICD-9 rates tended to be 
double VACCR rates, most IRRs were in the same direction and of similar magnitude, regardless of data source. Using 
either source, all cancers combined, most viral-infection-related cancers, lung cancer, melanoma, and leukemia had 
significantly elevated IRRs. Using ICD-9, eight additional IRRs were significantly elevated, most likely due to false positive 
diagnoses. Most ICD-9 SIRs were significantly elevated and all were higher than the corresponding VACCR SIR.
Conclusions: ICD-9 may be used with caution for estimating IRRs, but should be avoided when estimating 
incidence or SIRs. Elevated cancer risk based on VACCR diagnoses among HIV-infected veterans was consistent 
with other studies.
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sensitivity and positive predictive value (PPV) [9-14], with the expected 
tradeoff between the two [9,11,14]. Reasons for false positive incident 
cancer diagnoses include ascertainment of prevalent cancers, incorrect 
coding of cancer site, benign or in situ cancers incorrectly classified as 
malignant, and rule out or provisional diagnoses [9,11,14]. Although 
the false positive rate may be reduced using procedure codes as evidence 
of cancer treatment [9,11,14], systematic differences between patients 
who do and do not receive treatment may introduce bias. Such bias 
would be of particular concern for comparisons of cancer incidence 
in HIV-infected and uninfected persons, since HIV-infected cancer 
patients are less likely than uninfected patients to be treated [15,16].
Other studies of cancer incidence among PLWHA have used 
cancer registries to identify cancer diagnoses [1,17,18]. Registries aim 
to collect standardized information on all cancer diagnoses that occur 
within a defined population, such as residents of a defined geographic 
area [19,20]. They require substantial resources, but meet stringent 
quality standards [21].
To our knowledge, the impact on the results of epidemiologic 
analyses of using registry versus claims data for cancer diagnoses has 
not been studied. To assess this impact on studies of cancer incidence in 
HIV-infected versus uninfected persons, we compared findings using 
registry versus claims data to identify incident cancer diagnoses in the 
Veterans Aging Cohort Study (VACS), which includes HIV-infected 
veterans and demographically-matched uninfected veterans in the US. 
Previously, ICD-9 code diagnoses were used to study cancer incidence 
in this cohort [7,22]; subsequently VACS was linked to the Veterans 
Affairs Central Cancer Registry (VACCR), which seeks to identify all 
cancer cases diagnosed or treated at Veterans Health Administration 
(VHA) medical centers [23]. We hypothesized that VACCR diagnoses 
would have greater validity than ICD-9 code diagnoses and that the two 
data sources would lead to different study conclusions.
Materials and Methods
VACS consists of two cohorts. The larger VACS Virtual Cohort 
(VACS-VC) is based on national VHA databases (e.g., demographic, 
vital status, inpatient and outpatient encounters with associated 
diagnosis and procedure codes, pharmacy, laboratory results) with no 
patient-contact [24]. VACS-VC enrolls HIV-infected veterans when 
they begin HIV care in the VHA system and two matched uninfected 
patients also in VHA care. The VACS Eight Site Study (VACS-8) [25] 
recruits HIV-infected patients at Infectious Disease clinics(a subset 
of VACS-VC) and frequency-matched uninfected patients from the 
General Internal Medicine clinics at eight VHA facilities. VACS-
8 subjects complete surveys and provide consent to access medical 
charts. In both cohorts, subjects are matched on age, race/ethnicity, 
gender, and clinical site.VHA Connecticut Healthcare System and Yale 
University Institutional Review Boards have approved both cohorts and 
have granted VACS-VC a waiver of informed consent.
VACCR, which adheres to North American Association of 
Central Cancer Registries standards, maintains a database of cancer 
cases diagnosed or treated at the VHA, aggregated from local VHA 
medical center registries [23]. We linked VACS and VACCR to 
ascertain incident cancer cases. We then mapped ICD for Oncology, 
third edition (ICD-O-3) [26] topography and morphology codes from 
VACCR records and ICD-9 cancer diagnosis codes from VHA inpatient 
and outpatient encounter files to specific cancer types, consistent 
with Surveillance, Epidemiology, and End Results (SEER) recoding 
algorithms [27,28]. We required ICD-9 code diagnoses to be associated 
with at least one inpatient or two outpatient encounters on separate 
dates for the same cancer type, similar to methods used in prior VACS 
analyses [7,22,29]. The diagnosis date was the date provided by VACCR 
for VACCR diagnoses or the earliest ICD-9 code date for ICD-9 code 
diagnoses.
We ran parallel analyses to compare the findings using VACCR 
versus ICD-9 codes as the cancer diagnosis source. First, we assessed 
the validity of each data source for cancer-type-specific diagnoses 
using medical chart review as the gold standard; next, we compared 
HIV-status-specific, type-specific incidence rates and the association 
of HIV infection with cancer risk; and finally, we calculated HIV-
status-specific, type-specific standardized incidence ratios (SIRs) by 
comparing observed and expected numbers of cases based on SEER 
rates. Tables for IRR and SIR analysis results include ADC, cancer types 
established to be associated with HIV, and select common NADC. 
The appendix includes complete results for all specific cancer types. 
Statistical analyses were performed using SAS version 9.2 [30].We 
defined statistical significance as p<0.05 (two-sided).
Validity of VACCR and ICD-9 code diagnoses by chart review
We identified all potential incident cancer cases (excluding non-
melanoma skin cancers) from 1999-2008 for VACS-8 subjects at four 
VACS-8 sites with available electronic medical charts (Los Angeles, 
Pittsburgh, Bronx, Houston). Potential cases included all diagnoses 
identified from four sources: ICD-9 codes, VACCR, local VHA 
hospital cancer registries, or electronic medical record text searches 
for malignancy-related terms (“malignant”, “cancer”, “lymphoma”, 
“carcinoma”, etc.). We then adjudicated each potential case from the 
four sources by reviewing pathology, cytology, operative, radiology, and 
progress reports, as well as other records from the electronic medical 
chart. We compared sensitivity, specificity, PPV, and negative predictive 
value between VACCR and ICD-9 code diagnoses for all cancers 
combined and for specific cancer types, overall and by HIV status. 
Impact of VACCR and ICD-9 code diagnoses on cancer 
incidence rates and rate ratios
Using VACS-VC data from 1996-2008, we compared the impact 
of the two data sources on HIV-status-specific cancer incidence rates 
and on rate ratios (HIV-infected vs. uninfected). We conducted each 
analysis for all cancers combined and for specific cancer types. We 
calculated observation time from 180 days post-baseline (to remove 
prevalent cases) to the date of cancer diagnosis, death, last healthcare 
utilization date, or December 31, 2008. In the all-cancer analysis, we 
used the first incident primary cancer diagnosis per subject as the 
endpoint. For specific cancer types, the endpoint was the first type-
specific diagnosis.
We calculated age-, sex-, race/ethnicity-, and calendar-period-
standardized incidence rates (IR) using the person-year distribution of 
the entire cohort as the standard weights [31]. We used exact person-
time data calculation methods where time-dependent variables (i.e., 
age, calendar period) are classified at each day of observation [32]. The 
categories used for standardization were the same as those presented 
in Table 1.To quantify the association of HIV with cancer risk, we 
calculated incidence rate ratios (IRR) (HIV-infected versus uninfected) 
and 95% confidence intervals (CI) [31]. For the remainder of the text, 
IR and IRR refer to calculations using standardized rates. To examine 
the effects of missed cases due to healthcare outside the VHA system, 
we used the one inpatient/two outpatient encounter algorithm to count 
additional ICD-9 code cancer diagnoses from Medicare and Medicaid 
encounters to recalculate IRs and IRRs. 
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(i.e., had observation time after 180 days post-baseline). Subjects who 
contributed observation time were predominantly male (98%); about 
half were non-Hispanic black and about two-fifths were non-Hispanic 
white; approximately 70% were 35-54 years of age at baseline; and 
more than half entered the cohort in 1996-1999 (Table 1). The median 
observation time was 6.0 years for HIV-infected subjects and 7.7 years 
for uninfected subjects. The medical chart review from the four VACS-
8 sites included 3,222 subjects, whose baseline characteristics were 
similar to VACS-VC subjects, except that about 90%of VACS-8 subjects 
were enrolled during 2000-2005.
Validity of VACCR and ICD-9 code diagnoses by chart review
Medical chart review confirmed a total of 252 incident cancers 
in the four VACS-8 sites (Table 2). VACCR identified 229 potential 
cancers, and ICD-9 codes identified 369 potential cancers. Using chart 
review as the gold standard, overall VACCR type-specific sensitivity 
was slightly lower than ICD-9 code sensitivity(87% versus92%), but 
overall VACCR type-specific PPV was much higher(96% versus 63%), 
with 136 false positive ICD-9 code diagnoses, but only 10 false positive 
VACCR diagnoses. When we excluded 28 “cancers of unspecified site,” 
theICD-9 code PPV remained low (68%).
VACCR diagnosis sensitivity and PPV did not meaningfully differ 
by HIV status (Table 3). ICD-9 code diagnosis sensitivity also did not 
differ by HIV status, but PPV was lower for HIV-infected subjects 
(59% versus 69%). VACCR sensitivity was below 90% for four of the 
nine common cancer types shown in Table 3 (anal, liver, lung, Kaposi 
sarcoma), whereas ICD-9 code sensitivity was below 90% for only two 
of these cancer types (anal, leukemia). However, VACCR PPV was at 
least 90% for all of the common cancer types except oral cavity and 
pharynx, whereas ICD-9 code PPV was below 90% for all but non-
Hodgkin lymphoma. In all cases, PPV was lower using ICD-9 code than 
VACCR; the lowest ICD-9 code PPVs were for oral cavity and pharynx 
(23%) and colorectal (34%) cancers.
We compared the cancer diagnosis dates determined by the VACCR 
and ICD-9 codes (date of first code for the cancer type of interest) with 
the diagnosis date determined by the gold standard chart review. The 
VACCR diagnosis date was identical to the gold standard diagnosis 
date for 192 (88%) of the 219 cancer diagnoses identified by VACCR 
and confirmed by chart review. Of the 27 VACCR diagnosis dates that 
were incorrect, 24 (89%) were within one year of the gold standard 
date (median: 15 days, interquartile range: 4-54 days). The ICD-9 code 
diagnosis date was identical for 166 (71%) of the 233 cancer diagnoses 
identified by ICD-9 code and confirmed by chart review. Similar to 
VACCR, of the 67 ICD-9 diagnosis dates that were incorrect, 60 (90%) 
Impact of VACCR and ICD-9 code diagnoses on SIRs 
We calculated SIRs with Wald confidence limits [33] to compare 
cancer incidence in VACS with the SEER program cancer registries, 
which are representative of the US population [19]. For each cancer 
type, we multiplied age-, sex-, race/ethnicity-, and calendar-period-
specific SEER incidence rates [34] obtained using SEER*Stat version 
8.0.4 [35] by the stratified person-time in VACS-VC to calculate the 
expected number of cases. We selected the first type-specific diagnosis 
for type-specific SEER incidence rates and the first cancer diagnosis of 
any type for the all-cancer SEER incidence rates.
Results
There were 124,936 VACS-VC subjects enrolled during 1996-2008, 





N (%) N (%)
Sex Female 905 (2) 1,831 (2)
Male 37,218 (98) 76,118 (98)
Race/ethnicity Non-Hispanic white 14,792 (39) 31,149 (40)
Non-Hispanic black 18,593 (49) 36,738 (47)
Hispanic 2,741 (7) 6,055 (8)
Other/unknown 1,997 (5) 4,007 (5)
Age (years) <30 1,599 (4) 2,915 (4)
30-34 2,789 (7) 5,415 (7)
35-39 5,099 (13) 10,094 (13)
40-44 7,743 (20) 15,578 (20)
45-49 8,310 (22) 17,133 (22)
50-54 5,700 (15) 12,023 (15)
55-59 3,182 (8) 6,759 (9)
60-64 1,789 (5) 3,871 (5)
≥65 1,912 (5) 4,161 (5)
Calendar-period 1996-1999 21,493 (56) 45,393 (58)
2000-2002 6,698 (18) 13,750 (18)
2003-2005 6,034 (16) 11,720 (15)
2006-2008 3,898 (10) 7,086 (9)












Incident cancer No cancer Total
VACCR




No cancer 33† 2,982 3,015
Total 252 2,992 3,244
ICD-9




No cancer 19† 2,926 2,945
Total 252 3,062 3,314
PPV=Positive Predictive Value, NPV=Negative Predictive Value
*For subjects with >1 potential cancer, each cancer was counted separately. Subjects with no potential cancers were counted once. ICD-9 codes identified more subjects 
with >1 potential cancer, resulting in a higher total.
†False negative diagnoses include those with no cancer diagnosis according to VACCR or ICD-9 code, respectively, as well as those with incorrect coding of the cancer 
type (two VACCR diagnoses and nine ICD-9 code diagnoses).
Table 2: Validity of Veterans Affairs Central Cancer Registry (VACCR) versus ICD-9 code cancer-type-specific diagnoses, with medical chart review as the gold standard*.
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VACCR ICD-9
Sensitivity PPV Sensitivity PPV
HIV+ 124/144=86% 124/131=95% 131/144=91% 131/221=59%
HIV- 95/108=88% 95/98=97% 102/108=94% 102/148=69%
Oral cavity and pharynx 3/3=100% 3/6=50% 3/3=100% 3/13=23%
Colorectal 10/11=91% 10/11=91% 10/11=91% 10/29=34%
Anal 12/16=75% 12/13=92% 13/16=81% 13/20=65%
Liver 19/22=86% 19/19=100% 20/22=91% 20/24=83%
Lung 38/48=79% 38/38=100% 45/48=94% 45/56=80%
Prostate 51/56=91% 51/52=98% 52/56=93% 52/62=84%
Non-Hodgkin lymphoma 20/21=95% 20/20=100% 21/21=100% 21/23=91%
Leukemia 9/9=100% 9/10=90% 8/9=89% 8/10=80%
Kaposi sarcoma 10/12=83% 10/10=100% 12/12=100% 12/15=80%
Other specified cancers† 45/51=88% 45/46=98% 47/51=92% 47/89=53%
Cancers of unspecified site 2/3=67% 2/4=50% 2/3=67% 2/28=7%
*Cancer types with at least 10 VACCR or ICD-9 code diagnoses
†Cancer-type specific sensitivity and PPV for the following cancer types combined: esophagus, stomach, small intestine, biliary tract, pancreas, peritoneum and 
retroperitoneum, larynx, pleura, melanoma, breast, uterus or corpus, penis, testicular, bladder, kidney, brain and nervous system, thyroid, Hodgkin lymphoma, multiple 
myeloma 
Table 3: Sensitivity and positive predictive value (PPV) of Veterans Affairs Central Cancer Registry (VACCR) and ICD-9 code diagnoses by HIV status and for common 
cancer types* (chart review as gold standard).
*Includes cancers of unspecified type
Table 4: Age-, sex-, race/ethnicity-, and calendar-period-standardized incidence rates (IR, per 100,000 person-years), incidence rate ratios (IRR) and 95% confidence 
intervals (95% CI) for Veterans Affairs Central Cancer Registry (VACCR) diagnoses and Veterans Health Administration (VHA) ICD-9 code diagnoses for selected cancer 
types.
VACCR VHA ICD-9
Cancer type HIV status # cases  IR IRR 95% CI # cases IR IRR 95% CI
All cancers*
+ 2,421 1,103.0 1.93 (1.82, 2.05) 4,282 2,119.6 1.95 (1.86, 2.05)
- 3,194 571.2 5,525 1,087.0
Oral cavity &
pharynx
+ 120 51.3 1.30 (1.03, 1.64) 286 123.6 1.65 (1.40, 1.94)
- 227 39.4 427 75.0
Colorectal
+ 124 54.8 1.22 (0.97, 1.52) 376 162.5 1.99 (1.70, 2.32)
- 264 45.1 471 81.8
Anal
+ 149 62.0 28.14 (16.06, 49.32) 281 118.1 20.78 (14.24, 30.31)
- 13 2.2 33 5.7
Liver
+ 173 75.9 3.27 (2.50, 4.29) 272 118.9 2.70 (2.21, 3.31)
- 139 23.2 259 44.0
Lung
+ 445 195.8 1.87 (1.63, 2.14) 647 284.9 1.84 (1.64, 2.06)
- 614 104.9 894 155.0
Melanoma
+ 46 19.5 2.21 (1.40, 3.49) 110 47.3 1.66 (1.27, 2.17)
- 51 8.8 162 28.5
Cervical
+ 0 0.0 - (-) 10 4.0 5.57 (1.44, 21.54)
- 0 0.0 4 0.7
Prostate
+ 396 181.1 0.96 (0.85, 1.07) 588 276.4 0.98 (0.89, 1.08)
- 1,085 188.9 1,555 281.9
Penis
+ 11 4.8 4.59 (1.38, 15.27) 24 10.0 5.11 (2.19, 11.94)
- 6 1.0 11 2.0
Hodgkin 
lymphoma
+ 75 32.3 9.08 (5.09, 16.19) 136 58.4 6.63 (4.50, 9.78)
- 20 3.6 49 8.8
Non-Hodgkin 
lymphoma
+ 315 133.8 6.93 (5.35, 8.96) 627 271.1 6.68 (5.57, 8.00)
- 113 19.3 229 40.6
Leukemia
+ 51 22.2 2.02 (1.33, 3.08) 90 39.9 1.45 (1.10, 1.92)
- 63 11.0 156 27.6
Kaposi sarcoma
+ 227 94.4 519.61 (229.02, 1,178.9) 528 223.3 180.31
(115.18, 
282.26)
- 1 0.2 7 1.2
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were within one year of the gold standard date (median: 28 days, 
interquartile range: 6-116 days).
Impact of VACCR and ICD-9 code diagnoses on cancer 
incidence rates and rate ratios
In the VACS-VC, there were 6,010 VACCR incident cancer 
diagnoses (5,615 first primary cancers of any type) and 13,386 ICD-
9 code incident cancer diagnoses (9,807 first primary cancers of any 
type). All-cancer IRs per 100,000 person-years were about twice as high 
using ICD-9 code (IRHIV+=2,120, IRHIV-=1,087) compared to VACCR 
(IRHIV+=1,103, IRHIV-=571) diagnoses, regardless of HIV status (Table 
4). For a few cancer types (i.e., trachea and mediastinum, bone and 
joint, soft tissue, eye, and brain and nervous system cancers),number 
of diagnoses and consequent IRs were on the order of five- to fifty-
fold higher using ICD-9 code compared to VACCR (Appendix Table 
A1). The most extreme instance was cervical cancer, with no VACCR 
cases, but 14 ICD-9 code cases (Table 4).VACCR indicated that four of 
these cases were intraepithelial (i.e., in situ) cancers. Furthermore, a 
search for procedure codes (e.g., hysterectomy) and pharmacy records 
(e.g., cisplatin) that would suggest treatment of invasive cervical cancer 
provided insufficient evidence to definitely support an incident invasive 
cervical cancer diagnosis among any of the 14 ICD-9 code cases.
The all-cancer IRRs (HIV-infected vs. uninfected) were 1.93 (95% 
CI: 1.82, 2.05) for VACCR and 1.95, (95% CI: 1.86, 2.05) for ICD-9 
code (Table 4). Most type-specific IRRs were in the same direction and 
of similar magnitude, regardless of data source. Using either VACCR 
or ICD-9 code diagnoses, most viral-infection-related cancers (oral 
cavity and pharynx, anal, liver, and penis cancers; Hodgkin and non-
Hodgkin lymphoma; and Kaposi sarcoma), lung cancer, melanoma, 
and leukemia had significantly elevated IRRs. Using ICD-9 code 
diagnoses, colorectal, biliary tract, nasal cavity and middle ear, bone 
and joint, soft tissue, cervical, brain and nervous system cancers, and 
multiple myeloma were also significantly elevated (Table 4; Appendix 
Table A1).Among ADC, the magnitude of significantly elevated IRRs 
ranged from about 7 for non-Hodgkin lymphoma to 180 (ICD-9) to 
520 (VACCR) for Kaposi sarcoma. Significantly elevated NADC IRRs 
ranged from 1.30 (oral cavity and pharynx cancer) to almost 30 (anal 
cancer) using VACCR diagnoses and from 1.45 (leukemia) to about 21 
(anal cancer) using ICD-9 code diagnoses.
In our secondary analysis of outside utilization with Medicare/
Medicaid, we found that 48% of HIV-infected subjects and 36% of 
uninfected subjects accessed Medicare/Medicaid services between 1997 
and 2008. In the all-cancer analysis, the addition of Medicare/Medicaid 
diagnoses increased ICD-9 code first primary cancer diagnoses of any 
type by 19% for HIV-infected subjects, but only by 11% for uninfected 
subjects (Appendix Table A1). Therefore, adding Medicare/Medicaid 
ICD-9 code diagnoses to VHA ICD-9 code diagnoses resulted in higher 
IRRs (for all cancers combined and for specific cancer types). However, 
most results were qualitatively similar to results using VHA ICD-9 code 
diagnoses alone.
Impact of VACCR and ICD-9 code diagnoses on SIRs
The greater number of observed ICD-9 code diagnoses compared 
to VACCR diagnoses resulted in more censoring based on cancer 
VACCR VHA ICD-9
Cancer type HIV status Observed # cases Expected # cases SIR (95% CI) Observed # cases Expected # cases SIR (95% CI)
All cancers†
+ 2,421 1,407 1.72 (1.65, 1.79) 4,282 1,277 3.35 (3.25, 3.45)
- 3,194 3,669 0.87 (0.84, 0.90) 5,525 3,401 1.62 (1.58, 1.67)
Oral cavity &
pharynx
+ 120 61 1.96 (1.64, 2.35) 286 61 4.71 (4.19, 5.29)
- 227 154 1.48 (1.30, 1.68) 427 153 2.79 (2.53, 3.06)
Colorectal
+ 124 164 0.76 (0.64, 0.90) 376 162 2.31 (2.09, 2.56)
- 264 423 0.62 (0.55, 0.70) 471 420 1.12 (1.02, 1.23)
Anal
+ 149 6 23.05 (19.63, 27.07) 281 6 43.56 (38.75, 48.96)
- 13 16 0.82 (0.48, 1.42) 33 16 2.09 (1.49, 2.94)
Liver
+ 173 46 3.80 (3.28, 4.41) 272 45 5.98 (5.31, 6.74)
- 139 118 1.18 (1.00, 1.39) 259 118 2.20 (1.95, 2.48)
Lung
+ 445 216 2.06 (1.88, 2.26) 647 214 3.02 (2.79, 3.26)
- 614 564 1.09 (1.01, 1.18) 894 561 1.59 (1.49, 1.70)
Melanoma
+ 46 44 1.04 (0.78, 1.39) 110 44 2.50 (2.07, 3.01)
- 51 110 0.46 (0.35, 0.61) 162 109 1.48 (1.27, 1.73)
Cervical
+ 0 1 0.00 (-) 10 1 13.41 (7.21, 24.92)
- 0 2 0.00 (-) 4 2 2.32 (0.87, 6.18)
Prostate
+ 396 571 0.69 (0.63, 0.77) 588 558 1.05 (0.97, 1.14)
- 1,085 1,496 0.73 (0.68, 0.77) 1555 1456 1.07 (1.02, 1.12)
Penis
+ 11 2 5.91 (3.27, 10.67) 24 2 12.90 (8.64, 19.24)
- 6 5 1.24 (0.56, 2.75) 11 5 2.27 (1.26, 4.10)
Hodgkin 
lymphoma
+ 75 9 8.24 (6.57, 10.33) 136 9 14.97 (12.65, 17.71)
- 20 21 0.93 (0.60, 1.44) 49 21 2.29 (1.73, 3.02)
Non-Hodgkin 
lymphoma
+ 315 67 4.69 (4.20, 5.23) 627 67 9.42 (8.71, 10.19)
- 113 169 0.67 (0.55, 0.80) 229 169 1.36 (1.19, 1.54)
Leukemia
+ 51 35 1.44 (1.10, 1.90) 90 35 2.55 (2.07, 3.14)
- 63 90 0.70 (0.54, 0.89) 156 90 1.73 (1.48, 2.02)
Kaposi 
sarcoma
+ 227 8 28.07 (24.65, 31.97) 528 8 65.92 (60.53, 71.79)
- 1 18 0.05 (0.01, 0.39) 7 18 0.38 (0.18, 0.81)
*Expected numbers of cases are rounded to the nearest whole number. SIR calculations used the exact expected number of cases (unrounded).
†Includes cancers of unspecified type
Table 5: Observed and expected numbers of cancer cases, standardized incidence ratios (SIR), and 95% confidence intervals (95% CI) for Veterans Affairs Central Cancer 
Registry (VACCR) diagnoses and Veterans Health Administration (VHA) ICD-9 code diagnoses for selected cancer types*.
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diagnosis date for ICD-9 code diagnoses, yielding less observation time 
and consequently a lower number of expected cancer cases based on 
SEER rates (HIV+: 1,277 versus 1,407 cases; HIV-: 3,401 versus 3,669 
cases) (Table 5). The all-cancer SIR for HIV-infected subjects was 
almost twice as high for ICD-9 code diagnoses (SIR=3.35; 95% CI: 3.25, 
3.45) than for VACCR diagnoses (SIR=1.72; 95% CI: 1.65, 1.79). For 
uninfected subjects, VACCR identified fewer cancers than expected 
(SIR=0.87, 95% CI: 0.84, 0.90), but ICD-9 code diagnoses identified 
more cancers than expected (SIR=1.62, 95% CI: 1.58, 1.67). 
Using VACCR diagnoses, with the exception of melanoma, cancer 
types with significantly elevated IRRs (most viral-infection-related 
cancers, lung cancer, and leukemia) in HIV-infected subjects also had 
significantly elevated SIRs (Table 5). Biliary tract, nasal cavity and 
middle ear, larynx, and pleura cancers were also significantly elevated 
(Appendix Table A2). For uninfected subjects, SIRs were significantly 
elevated for oral cavity and pharynx, esophagus, larynx, lung, and 
pleura cancers, but the majority of SIRs were less than or around 1.0.
Using ICD-9 code diagnoses, most SIRs for both HIV-infected 
and uninfected subjects were significantly elevated (Table 5; Appendix 
Table A2). Furthermore, all of the ICD-9 SIRs were greater than the 
corresponding VACCR SIRs. The strikingly higher number of ICD-9 
code than VACCR observed cases for trachea and mediastinum, bone 
and joint, soft tissue, brain and nervous system, and cervical cancers 
resulted in markedly higher SIRs by ICD-9 code than by VACCR.
Discussion
This investigation not only reviewed the validity of cancer registry 
and ICD-9 code diagnoses compared to medical chart review, but also 
examined the impact of these data sources in a study of the association 
between HIV status and cancer risk. As expected, we found VACCR 
diagnoses to be more valid than ICD-9 code diagnoses. With chart 
review as gold standard, we found that both VACCR and ICD-9 code 
diagnoses exhibited high sensitivity, missing only about 10% of cancer 
cases. However, the validity of the two data sources diverged when 
we evaluated PPV, which was appreciably lower using ICD-9 codes. 
Furthermore, the VACCR cancer diagnosis date was more accurate 
than the ICD-9 code diagnosis date, with 88% of VACCR diagnosis 
dates, but only 71% of ICD-9 diagnosis dates, in exact agreement with 
the gold standard. Based on these results, we can adopt VACCR as our 
preferred data source for cancer epidemiologic analyses, and can predict 
that the low PPV (and resultant high proportion of false positive cases) 
for ICD-9 code diagnoses will lead to artifactually inflated estimates of 
IRs and SIRs.
Our analyses using VACCR diagnoses were broadly consistent 
with previous findings [2,3], providing face validity for our adoption 
of VACCR diagnoses in future analyses. First, the incidence of the 
two main ADC, Kaposi sarcoma and non-Hodgkin lymphoma, was 
appreciably elevated among PLWHA as shown by both IRRs and SIRs. 
Second, our all-cancer IRR, as well as our SIR for PLWHA, were both 
almost two, similar to the result for all-NADC combined in a meta-
analysis of the incidence of NADC in PLWHA compared to the general 
population [3]. Third, the incidence of oral cavity and pharynx, anal, 
liver, lung, and penis cancers, Hodgkin lymphoma, and leukemia, 
NADCs well-established to be elevated among PLWHA [2,3], was 
significantly elevated among PLWHA according to both IRRs and SIRs.
Consistent with our prediction, the all-cancer IR was about two-
fold higher using ICD-9 code than VACCR diagnoses. However, 
for some cancer types (e.g., bone and joint and brain and nervous 
system), the number of diagnoses was many-fold higher using ICD-9 
codes, resulting in IRs (and SIRs) that were biased upward many-fold. 
Interestingly, in spite of the inflated IRs using ICD-9 code diagnoses, 
many type-specific IRRs were similar across the two data sources, 
apparently due to similar type-specific multiplicative inflation factors 
(ICD-9 IRs versus VACCR IRs) across HIV status. Consistent with 
this observation, the 2009 VACS study that used ICD-9 code cancer 
diagnoses reported IRs that we now know to be inflated. However, IRRs 
for anal, liver, lung, and prostate cancers, Hodgkin lymphoma, non-
Hodgkin lymphoma, and Kaposi sarcoma were of similar magnitude 
and significance to the VACCR IRRs reported here [7]; only the cervical 
cancer IRR was notably erroneous. Furthermore, in the current study, 
IRRs for other cancer types differed across the two data sources. For 
example, for colorectal cancer, which is generally found not to have 
elevated incidence in PLWHA, the VACCR IRR was 1.22 (95% CI: 
0.97, 1.52), whereas the ICD-9 code IRR was 1.99 (95% CI: 1.70, 2.32) 
(Table 4). Finally, for other cancer types, such as biliary tract and nasal 
cavity and middle ear, the magnitude of the IRR was similar across 
the two data sources, but the IRR based on ICD-9 code diagnoses was 
statistically significant, whereas the IRR based on VACCR diagnoses 
was not. 
The effect of low PPV and large number of false positive ICD-9 
code diagnoses was more evident in our SIR analysis, with ICD-9 code 
diagnoses resulting in inflated SIRs, significantly greater than 1.0, for 
most cancer types in both HIV-infected and uninfected subjects. The 
all-cancer SIR of 3.35 for HIV-infected subjects was unrealistically high 
[3]. Although we would expect cancer incidence in uninfected veterans 
to be higher than in the general US population due to higher prevalence 
of certain cancer risk factors, such as smoking [36] and hepatitis C 
virus infection [37], the all-cancer SIR of 1.62 was also unrealistically 
high. Furthermore, cancer types that appear to be unrelated to HIV-
infection, including colorectal, pancreas and bladder cancers [3], 
exhibited significantly elevated SIRs among PLWHA.
The inflated ICD-9 code SIRs, which resulted from comparing 
cancer incidence rates measured by ICD-9 code in the VACS to 
cancer incidence rates measured by cancer registry in the general US 
population, highlight the danger of comparing disease risk in two 
populations for which the method of case ascertainment differed. On 
the other hand, the VACCR SIRs, which we established to be more 
valid, compared cancer incidence rates measured by cancer registry in 
both populations. 
This study had appreciable strengths. Few studies have compared 
both registry and claims data to a medical chart review; and to our 
knowledge, no study has examined data source impact on epidemiologic 
analyses. VACS has the strengths of a very large sample size in the 
VACS-VC, providing generally high statistical power for epidemiologic 
analyses, combined with the smaller VACS-8 sample, providing in-
depth medical record data for validation analyses. Thus, this study was 
able to review the fine detail of cancer data accuracy with chart review, 
while also calculating IRs, IRRs, and SIRs for many specific cancer 
types in the larger sample.
Our study also had limitations. Since our cohort was 98% male, 
we had scant statistical power to assess female cancer types and were 
unable to generalize our results to women. In addition, we did not 
review the medical chart for each of the 3,222subjects from the four 
VACS-8 sites. However, we believe that the text search for malignancy-
related terms should have rendered all of the subjects with potential 
incident cancer diagnoses.
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As demonstrated in this study, analyses that use VACCR data will 
underestimate cancer incidence. First, although the VACCR diagnoses 
exhibited a relatively high sensitivity, VACCR did miss 13% of cases. 
Second, the all-cancer SIR for uninfected subjects was significantly 
below 1.0, suggesting that VACCR is missing cancer cases since we 
would expect cancer incidence for uninfected veterans to be greater 
than in the general population. Finally, we found that adding Medicare/
Medicaid ICD-9 code diagnoses to VHA ICD-9 code diagnoses 
resulted in 19% more diagnoses among HIV-infected veterans and 11% 
more diagnoses among uninfected veterans. Although some of these 
diagnoses were certainly false positives, many would be true positives 
not captured by VACCR.
The underestimation of cancer incidence in the VACS-VC using 
VACCR diagnoses would result in SIRs that are biased downward. 
Given the differential outside utilization with Medicare/Medicaid 
apparently resulting in a greater proportion of outside cancer diagnoses 
among HIV-infected veterans, we can project that IRRs would be biased 
downward as well. Unfortunately, we were unable to directly show how 
outside utilization may affect IRRs based on VACCR diagnoses.
In conclusion, ICD-9 codes are a convenient source of data because 
of low cost and availability, especially since linking cancer registry data 
to HIV cohorts is not always feasible. However, the low PPV of ICD-
9 code diagnoses resulted in overestimation of incident cancers cases, 
IRs, and SIRs, such that ICD-9 code diagnoses should not be used 
to estimate these measures. Although VACCR and ICD-9 code IRRs 
tended to be similar, there were meaningful exceptions, indicating that 
ICD-9 code IRR estimates should be interpreted with caution. Elevated 
cancer risk based on VACCR diagnoses among HIV-infected veterans 
was consistent with other studies. Cancer registry diagnoses should be 
used for epidemiologic analyses whenever feasible.
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